Featuring a slide presentation and related discussion from Prof Karim Fizazi, including the following topics:
- PROTEUS Phase III trial evaluating the addition of apalutamide to standard therapy in high-risk localized prostate cancer (0:00)
- Time to testosterone recovery during treatment suspension in the Phase III EMBARK trial of enzalutamide and leuprolide in nonmetastatic prostate cancer (5:05)
- Radiographic progression-free survival subgroup analysis in the PSMAddition Phase III trial of 177Lu-PSMA-617 in metastatic hormone-sensitive prostate cancer (6:58)
- TALAPRO-3: Efficacy of talazoparib and enzalutamide in metastatic hormone-sensitive prostate cancer harboring homologous recombination repair gene alterations (8:16)
- Phase I/II PETRANHA study of novel PARP inhibitor saruparib in metastatic hormone-sensitive prostate cancer (10:52)
- Phase II A-DREAM trial of androgen deprivation therapy interruption in patients with metastatic hormone-sensitive prostate cancer responding to androgen receptor pathway inhibitor (13:23)
- Overall survival by duration of enzalutamide treatment received in the Phase III ARCHES trial (15:21)
- Efficacy of capivasertib and abiraterone in the Phase III CAPItello-281 trial for patients with PTEN-deficient metastatic hormone-sensitive prostate cancer (16:24)
- Phase I AcTION study of 225Ac-PSMA-617 in patients with metastatic castration-resistant prostate cancer (mCRPC) with or without prior 177Lu-PSMA radioligand therapy (18:16)
- Phase III PSMAfore trial of 177Lu-PSMA-617 in progressive mCRPC; ongoing Phase III trials of radioligands in mCRPC (19:54)
- Ongoing Phase III OMAHA-004 trial of CYP11 inhibitor opevesostat versus next-generation hormonal agent switch in patients with mCRPC and 1 prior next-generation hormonal agent (23:14)